Chicago, IL 4/9/12 (StreetBeat) -- Generic drugmaker Watson Pharmaceuticals Inc (NYSE: WPI) said U.S. health regulators approved its copycat version of ViroPharma Inc's (Nasdaq: VPHM) antibiotic Vancocin.Separately, ViroPharma said the U.S. Food and Drug Administration declined its citizen petition, which was filed to prevent Watson from launching the generic version.
Shares of ViroPharma were trading down 18 percent at $23.40 in premarket.
Watson said it has started shipping the drug, which recorded sales of $332 million for the 12 months ended February 29, 2012.
ViroPharma shares closed at $28.61 on Monday on the Nasdaq.
Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.
StreetBeat Disclaimer
No comments:
Post a Comment